endocannabinoid

Cannabinoid Signaling in the Skin: Therapeutic Potential of the “C(ut)annabinoid” System

ABSTRACT This concept was further supported by a small, single-blind, split-face study, in which a cream containing 3% Cannabis seed extract was applied twice daily to the cheeks of patients for 12 weeks. The treatment was found to be efficient in reducing sebum production and erythema compared to the vehicle treated side [124]. Moreover, a …

Cannabinoid Signaling in the Skin: Therapeutic Potential of the “C(ut)annabinoid” System Read More »

Sep 28 2019

Endocannabinoid system in systemic lupus erythematosus: First evidence for a deranged 2-arachidonoylglycerol metabolism.

ABSTRACT The endocannabinoid (eCB) system plays a key role in many physiological and pathological conditions and its dysregulation has been described in several rheumatological and autoimmune diseases. Yet, its possible alteration in systemic lupus erythematosus (SLE) has never been investigated. Here, we aimed filling this gap in plasma and peripheral blood mononuclear cells (PBMCs) of …

Endocannabinoid system in systemic lupus erythematosus: First evidence for a deranged 2-arachidonoylglycerol metabolism. Read More »

Sep 28 2019

Cannabinoids in attention-deficit/hyperactivity disorder: A randomised-controlled trial.

Abstract Adults with ADHD describe self-medicating with cannabis, with some reporting a preference for cannabis over ADHD medications. A small number of psychiatrists in the US prescribe cannabis medication for ADHD, despite there being no evidence from randomised controlled studies. The EMA-C trial (Experimental Medicine in ADHD-Cannabinoids) was a pilot randomised placebo-controlled experimental study of …

Cannabinoids in attention-deficit/hyperactivity disorder: A randomised-controlled trial. Read More »

Sep 24 2019

Cannabidiol reduces the anxiety induced by simulated public speaking in treatment-naïve social phobia patients.

ABSTRACT Generalized Social Anxiety Disorder (SAD) is one of the most common anxiety conditions with impairment in social life. Cannabidiol (CBD), one major non-psychotomimetic compound of the cannabis sativa plant, has shown anxiolytic effects both in humans and in animals. This preliminary study aimed to compare the effects of a simulation public speaking test (SPST) …

Cannabidiol reduces the anxiety induced by simulated public speaking in treatment-naïve social phobia patients. Read More »

Sep 1 2019

Cannabinoid Signaling in the Skin: Therapeutic Potential of the “C(ut)annabinoid” System

Endocannabinoid system in systemic lupus erythematosus: First evidence for a deranged 2-arachidonoylglycerol metabolism.

Cannabinoids in attention-deficit/hyperactivity disorder: A randomised-controlled trial.

JOIN OUR NEWSLETTER

CONNECT WITH US

About

LEARN

Shop

These statements have not been evaluated by the FDA. This product is not intended diagnose, treat, cure or prevent disease.